Dendreon gives Provenge update

Dendreon Corp. (NASDAQ:DNDN) said it plans to submit an amendment to its BLA for Provenge sipuleucel-T to treat advanced prostate cancer by mid-November. Dendreon previously said it expected to submit the amendment next quarter. The company also said it expects FDA action on the application in mid-2010. ...